Company name
Humion AG
Company profile
Humion is an emerging Swiss biotech, pioneering the next generation of TCR-based T-cell therapies for solid tumors. Our edge: cutting-edge TCR discovery technology. We identify validated, tumor-reactive TCRs with precision and speed. Our lead program, Humion-1, takes on non-small cell lung cancer. The pipeline expands across solid tumors. We seek partners who want to add the value of validated TCRs to their platform.
Date, time and room information
Monday, May 4, 15:45 - 16:00, room Singapore
Category
Emerging biotech company
Title of the presentation
Humion: Precision TCRs. Real Tumor Impact.
Speaker information
| Name | Position | Institution |
|---|---|---|
| Omar Hasan Ali, MD | Co-Founder | Humion AG |
